Ivoclar Vivadent files complaints against GC Corporation and GC America

 Schaan, Liechtenstein – 17 March 2017

Ivoclar Vivadent files U.S. ITC and U.S. District Court complaints against GC Corporation and GC America

Ivoclar Vivadent, the innovator and manufacturer of IPS e.max® products, announced today that it has filed a complaint with the U.S. International Trade Commission and in the U.S. District Court for the Northern District of Illinois against GC Corporation and GC America, Inc. (collectively “GC”).

The ITC complaint requests that GC's InitialTM LiSi Press products are blocked from being imported into the United States, and that the distribution and sale of any such domestic inventories be stopped. The ITC and District Court complaints assert that GC's InitialTM LiSi Press products infringe Ivoclar Vivadent's U.S. Patent Nos. 6,455,451; 6,517,623; 6,802,894; and 7,452,836 protecting Ivoclar Vivadent's lithium silicate glass ceramics technology. Ivoclar Vivadent considers its lithium silicate glass ceramics technology, and the patents protecting this technology, to be very valuable and it will remain resolute and active in vigorously enforcing its patents in this area.

About Ivoclar Vivadent
Ivoclar Vivadent, headquartered in Schaan, Liechtenstein, is one of the world's leading manufacturers of innovative material systems for high-quality dental applications. The company's success is based on a comprehensive portfolio of products and systems, strong research and development capabilities and a clear commitment to training and further education. The company has wholly owned subsidiaries in 25 countries, and it employs over 3,300 people worldwide. More information about Ivoclar Vivadent is available at www.ivoclarvivadent.com.